Heparin

$7.75+ Billion Blood Collection Devices (Tubes, Needles & Syringes, Blood Bags, Monitors) Markets - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 9, 2022
Medical Devices, Health, Degenerative disease, Incidence, USD, Trauma, Diagnosis, Hospital, Nursing, Becton, Accident, Transplant, Infection, Prevalence, Method, EDTA, 3D ultrasound, Growth, CAGR, Quest Diagnostics, Becton, Dickinson and Company headquarters, Medical device, Serum, Plasma, Heparin

The "Global Blood Collection Devices Market by Product (Tubes (Plasma (EDTA, Heparin), Serum), Needles & Syringes, Blood Bags, Monitors), Method (Manual, Automated), Application (Diagnostic, Therapeutic), End User (Hospitals, Blood Banks) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Blood Collection Devices Market by Product (Tubes (Plasma (EDTA, Heparin), Serum), Needles & Syringes, Blood Bags, Monitors), Method (Manual, Automated), Application (Diagnostic, Therapeutic), End User (Hospitals, Blood Banks) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global blood collection devices market is projected to reach USD 7.8 billion by 2026 from USD 5.7 billion in 2021, at a CAGR of 6.0% during the forecasted year.
  • The blood collection devices available in the market are based on two major methods - manual and automated blood collection methods.
  • However, the most widely used method in the blood collection devices market is manual blood collection.

Low Molecular Weight Heparin Market Forecast to 2028 - Global Analysis by Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 2, 2022
Pharmaceutical, Health, Other Health, Myocardial infarction, Risk, LMWH, ACS, Patient, Anticoagulant, Hospital, Thrombosis, Heparin, Enoxaparin sodium, Plasma, Calcium hypochlorite, COVID-19, Nadroparin calcium, Syringe, Deep vein thrombosis, Geography, CAGR, Atomic mass, Dalteparin sodium, Pulmonary embolism, Half-life, Osteoporosis, UFH, HIT, Acute coronary syndrome, Pharmaceutical industry, Sodium, Application, Tinzaparin sodium

The low molecular weight fractions of heparin have the molecular weight of ~3,500-8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter.

Key Points: 
  • The low molecular weight fractions of heparin have the molecular weight of ~3,500-8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter.
  • The global low molecular weight heparin market, based on product type, is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others.
  • The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes.
  • The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others.

PURIFY Investigators Announce First Patient Enrolled in a US Randomized Controlled IDE Trial Evaluating Seraph 100 for the Treatment of Septic Shock

Retrieved on: 
Wednesday, March 2, 2022
Health, Medical Devices, Infectious Diseases, Surgery, Clinical Trials, Research, Science, Infection, Family, Patient, Hospital, Virus, Heparin, Treatment, Uniformed Services University of the Health Sciences, Safety, News, Jean-Louis Vincent, Knowledge, Department of Defense Serum Repository, Bacteria, FDA, Pandemic, DARPA, COVID-19, Communication, EUA, Karger Publishers, Clinical trial, Sepsis, Good Samaritan Hospital, Person, Henry M. Jackson Foundation for the Advancement of Military Medicine, CE, MD, Department, Outline of health sciences, IDE, Fungus, Randomized controlled trial, Pharmaceutical industry, EU, Seraph, ExThera Medical Corporation, Seraph 100, EXTHERA MEDICAL CORPORATION, SERAPH 100

Investigators today announced the first patient enrollment in the Blood Purification for the Treatment of Pathogen Associated Shock ( PURIFY-RCT ) trial.

Key Points: 
  • Investigators today announced the first patient enrollment in the Blood Purification for the Treatment of Pathogen Associated Shock ( PURIFY-RCT ) trial.
  • With this study, we are determining if this therapy improves clinically relevant outcomes while showing no evidence of harm in a randomized controlled trial design.
  • Now we are rigorously testing whether Seraph plus cutting-edge sepsis care will save lives in the hospital.
  • The study is expected to randomize approximately 60 patients over a 12-month timeframe, with preliminary results expected in early 2023.

Techdow USA Announces Launch of Heparin Sodium Injection, USP in the United States

Retrieved on: 
Tuesday, February 8, 2022
General Health, Pharmaceutical, Health, Other Health, Heparin, Bleeding, Sale, USP, Akwa Ibom State Association of Nigeria, USA Inc., FDA, HIT, Thrombocytopenia, Environment, Fine chemical

Techdow USA Inc. (Techdow USA), a vertically integrated generic injectables company, today announced the launch of its Heparin Sodium Injection, USP in the US market.

Key Points: 
  • Techdow USA Inc. (Techdow USA), a vertically integrated generic injectables company, today announced the launch of its Heparin Sodium Injection, USP in the US market.
  • Techdow USA is excited to bring this critical product to institutions and networks in need of an affordable and reliable source of heparin, said Darren Alkins, Chief Executive Officer of Techdow USA.
  • Techdow USA specializes in the sale of generic injectable pharmaceuticals and will look to expand their product portfolio and pipeline to better serve customer and patient needs.
  • To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico

Retrieved on: 
Thursday, February 3, 2022
Science, Biotechnology, Research, General Health, Health, Medical Devices, Infectious Diseases, Hospitals, Seraph, Infection, CEO, Fresenius Medical Care, Patient, Kidney, FMS, Mortality, MRSA, Critical care, Communication, Dialysis, Person, NDT, Pandemic, FME, Bacteria, COVID-19, ICU, Partnership, Heparin, Treatment, CE, Fungus, DARPA, Company, Blood, Jean-Louis Vincent, Frankfurt Stock Exchange, News, Sepsis, COSA, Severe acute respiratory syndrome coronavirus 2, Virus, EUA, FDA, New, Emergency Use Authorization, Hospital, Pharmaceutical industry, Vaccine, European, EU

ExThera Medical and Fresenius Medical Care, the worlds leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExTheras Seraph 100 Microbind Affinity Blood Filter in Mexico.

Key Points: 
  • ExThera Medical and Fresenius Medical Care, the worlds leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExTheras Seraph 100 Microbind Affinity Blood Filter in Mexico.
  • In 2021, ExThera Medical and Fresenius Medical Care partnered to distribute the Seraph 100 in select European countries.
  • The Seraph 100 is used in intensive care medicine for the reduction of pathogens in the blood and can be operated with Fresenius Medical Care acute dialysis machines.
  • The Seraph 100 has been used to treat more than 800 COVID-19 patients, in over 70 hospitals, globally.

The Worldwide Heparin Industry is Expected to Reach $10 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 20, 2022
Medical Supplies, Health, Hospitals, Other Science, Science, Pharmaceutical, Cardiology, CDC, Heparin, Medicine, Pulmonary embolism, COVID-19, Respiratory disease, Cardiopulmonary bypass, Patient, LMW, Center, Korea Disease Control and Prevention Agency, Hemofiltration, Atomic mass, Infarction, LMWH, Severe acute respiratory syndrome coronavirus 2, Hip, Growth, Atrial fibrillation, Acute coronary syndrome, Skin, Viral disease, Thrombosis, Deep vein thrombosis, UFH, CT, Risk, Blood, Conditional sentence, Pharmaceutical industry

Heparin is widely used as an anticoagulant in medicine that acts as a blood thinner.

Key Points: 
  • Heparin is widely used as an anticoagulant in medicine that acts as a blood thinner.
  • Acute coronary syndrome, pulmonary embolism, atrial fibrillation, deep vein thrombosis, cardiopulmonary bypass & hemofiltration during cardiac surgery can be treated by the use of heparin.
  • The increasing incidences of chronic diseases will positively influence the expansion of the heparin market across the globe.
  • Moreover, the introduction of highly precise and upgraded heparin products by the market players will boost the growth of the heparin market.

Patient Enrollment is Complete in the DOD-Funded Study of Extracorporeal Hemopurification of Critically Ill COVID-19 Patients

Retrieved on: 
Tuesday, January 18, 2022
Medical Devices, Health, Infectious Diseases, Research, Science, Biotechnology, Seraph, RCT, Survival, COVID 19, Sepsis, Patient, Heparin, News, Jean-Louis Vincent, DOD, Union, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, COVID-19, Observational study, Virus, ICU, Safety, EUA, Pandemic, Bacteria, Infection, DARPA, CE, Physician, Food, Communication, FDA, Hospital, Fungus, COVID, Pharmaceutical industry, EU, ExThera Medical Corporation, Seraph 100, EXTHERA MEDICAL CORPORATION, SERAPH 100

PURIFY OBS , an observational study of critically-ill COVID patients treated with the Seraph 100 Microbind Affinity Blood Filter (Seraph 100), has recently completed enrollment.

Key Points: 
  • PURIFY OBS , an observational study of critically-ill COVID patients treated with the Seraph 100 Microbind Affinity Blood Filter (Seraph 100), has recently completed enrollment.
  • Observations included dramatic improvement in survival and reduction in median ICU length of stay for patients treated with the Seraph 100 vs controls.
  • We expect the first peer-reviewed PURIFY-OBS clinical trial publication soon, now that the study has concluded.
  • ExThera Medicals extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis and other severe infections.

Treatment for Critically Ill COVID Patients Results in Significant Improvement in Survival Rate According to New Study

Retrieved on: 
Tuesday, January 11, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Infectious Diseases, Seraph, Heparin, Survival, Sepsis, Patient, News, Jean-Louis Vincent, Survival rate, Intubation, Person, COVID-19, Virus, EUA, Transplant, Â, Pandemic, Bacteria, Infection, DARPA, CE, Nephrology Dialysis Transplantation, Communication, COSA, Treatment, FDA, Subclinical infection, Hospital, Omicron, COVID, Fungus, ICU, Pharmaceutical industry, EU, ExThera Medical Corporation, Seraph 100, EXTHERA MEDICAL CORPORATION, SERAPH 100

Few treatments are available for critically ill COVID patients in the ICU.

Key Points: 
  • Few treatments are available for critically ill COVID patients in the ICU.
  • In addition, patients treated earlier in their ICU with the Seraph 100 may avoid intubation and mechanical ventilation.
  • The new findings, published in Nephrology Dialysis Transplantation , found:
    There is still a need for therapeutic treatment options, especially in critically ill patients, as COVID variants such as Omicron continue to emerge.
  • ExThera Medicals extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis and other severe infections.

Biocom California Selects New Chair for its Board of Directors

Retrieved on: 
Monday, January 10, 2022
Research, Medical Devices, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Other Professional Services, CONNECT, Research, LinkedIn, Biotechnology, Biology, Division, Genomics, Conrad, Female, Single-frequency network, Public policy, Therapy, Cancer, Association, Heparin, RNA, COVID-19, Tulane University School of Medicine, State Bar of California, STEM, Infection, Advisory Council, Baxter International, Patient, Solution, CFO, Glycogen storage disease, Claudia Shear, University of California, San Diego, University, San Francisco Bay Area, UC, CEO, Photography, 4th Tony Awards, Goal, La Jolla Playhouse, Dean, TEGA, Project Concern International, VIII, Board, Pharmaceutical industry, Biochemistry, Facebook, Twitter

Biocom California, the association representing the California life science industry, today announced that it has named a new board chair and chair elect.

Key Points: 
  • Biocom California, the association representing the California life science industry, today announced that it has named a new board chair and chair elect.
  • Timothy Scott, CEO of TEGA Therapeutics is the new chair, and Sabrina Martucci Johnson, CEO of Dar Bioscience, is the chair elect.
  • These board leadership positions are crucial for shaping Biocom Californias goals and implementing new programs, said Joe Panetta, president and CEO of Biocom California.
  • In addition to announcing the new chair and chair elect, Biocom California also named the remainder of its board officers, who are as follows:
    Biocom California is the leader and advocate for Californias life science sector.

Lui Franciosi To Monitor the Safety and Efficacy of Nebulized Heparin for the Treatment of COVID-19

Retrieved on: 
Thursday, January 6, 2022
Chronic pain, University, Safety, COVID-19, Severe acute respiratory syndrome coronavirus 2, Lung, Review, Research, Patient, YouTube, University of Warwick, COVID, University of British Columbia, Simon Fraser University, Lyme disease, Diffuse alveolar damage, Pfizer–BioNTech COVID-19 vaccine, Yolk sac, Master, Suggestion, Pharmacology, Mortality, GLOBE, Heparin, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi will be monitoring the safety and efficacy of nebulized heparin for the treatment of SARS-CoV-2, i.e., COVID-19.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi will be monitoring the safety and efficacy of nebulized heparin for the treatment of SARS-CoV-2, i.e., COVID-19.
  • For more information about Lui Franciosi and his company Franciosi Consulting Ltd., please visit https://franciosiconsulting.com/ or his YouTube Channel https://www.youtube.com/channel/UC7PSoeH8yN-HuLg5xFi5Qxw/ .
  • Lui Franciosi is a pharmacologist and consultant with over 20 years of executive experience collected in the pharmaceutical and senior care industries.
  • He also studied business at the University of Warwick in the U.K. Lui Franciosi founded Franciosi Consulting Ltd. in 2015 and is the President and CEO.